Patents by Inventor Mark E. Shannon
Mark E. Shannon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150220685Abstract: A method for determining bias across two domains comprising gene expression data. The method can comprise (a) providing a first domain and a second domain; (b) obtaining information indicative of a bias within the first domain; (c) obtaining information indicative of a bias within the second domain; and (d) using the information indicative of the bias within the first domain and the information indicative of the bias within the second domain to produce an indication of bias across the two domains.Type: ApplicationFiled: April 16, 2015Publication date: August 6, 2015Inventors: Mark E. Shannon, Mark F. Oldham, David W. Ruff
-
Patent number: 9026371Abstract: A method for determining bias across two domains comprising gene expression data. The method can comprise (a) providing a first domain and a second domain; (b) obtaining information indicative of a bias within the first domain; (c) obtaining information indicative of a bias within the second domain; and (d) using the information indicative of the bias within the first domain and the information indicative of the bias within the second domain to produce an indication of bias across the two domains.Type: GrantFiled: September 11, 2009Date of Patent: May 5, 2015Assignee: Applied Biosystems, LLCInventors: Mark E. Shannon, Mark F. Oldham, David W. Ruff
-
Patent number: 8535878Abstract: The present teachings provide methods, compositions, and kits for detecting the presence of protein aggregates. In some embodiments, the protein aggregate is treated with a labeled precursor, and the labeled precursor is incorporated into the protein aggregate to form a labeled protein aggregate. The labeled protein aggregate is then measured, thus detecting the presence of the protein aggregate. In some embodiments, the labeled protein aggregate is detected by interaction of labeled precursors, for example by a proximity ligation assay.Type: GrantFiled: May 2, 2007Date of Patent: September 17, 2013Assignee: Applied Biosystems, LLCInventors: David W. Ruff, Mark E. Shannon, Kenneth J. Livak, Karl J. Guegler, Kevin M. Hennessy
-
Publication number: 20110287436Abstract: Methods of detecting at least one analyte and at least one nucleic acid in a sample are provided. Reagents for carrying out the methods are also provided.Type: ApplicationFiled: July 29, 2011Publication date: November 24, 2011Applicant: Applied Biosystems, LLCInventors: Mark E. Shannon, David W. Ruff
-
Patent number: 8012685Abstract: Methods of detecting at least one analyte and at least one nucleic acid in a sample are provided. Reagents for carrying out the methods are also provided.Type: GrantFiled: July 31, 2007Date of Patent: September 6, 2011Assignee: Applied Biosystems, LLCInventors: Mark E. Shannon, David W. Ruff
-
Publication number: 20100036616Abstract: A method for determining bias across two domains comprising gene expression data. The method can comprise (a) providing a first domain and a second domain; (b) obtaining information indicative of a bias within the first domain; (c) obtaining information indicative of a bias within the second domain; and (d) using the information indicative of the bias within the first domain and the information indicative of the bias within the second domain to produce an indication of bias across the two domains.Type: ApplicationFiled: September 11, 2009Publication date: February 11, 2010Applicant: Life Technologies CorporationInventors: Mark E. Shannon, Mark F. Oldham, David W. Ruff
-
Publication number: 20040137589Abstract: Presented are a novel myosin-like protein particularly expressed in human heart and muscle, isolated nucleic acids encoding the myosin-like protein, compounds and compositions derivable directly or indirectly therefrom, and diagnostic and therapeutic methods for using the same.Type: ApplicationFiled: November 26, 2003Publication date: July 15, 2004Inventors: Yizhong Gu, Yonggang Ji, Sharron Gaynor Penn, David Kagen Hanzel, David-Russell Rank, Wensheng Chen, Mark E. Shannon
-
Publication number: 20040078837Abstract: The invention provides isolated nucleic acids that encode MDZ3, MDZ4, MDZ7 and MDZ12, and fragments thereof, vectors for propagating and expressing MDZ3, MDZ4, MDZ7 and MDZ12 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel MDZ3, MDZ4, MDZ7 and MDZ12 isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human MDZ3, MDZ4, MDZ7 and MDZ12 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human MDZ3, MDZ4, MDZ7 or MDZ12 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the MDZ3, MDZ4, MDZ7 or MDZ12 nucleic acids, proteins, and antibodies of the present invention.Type: ApplicationFiled: August 2, 2001Publication date: April 22, 2004Inventors: Mark E. Shannon, Yizhong Gu, Cung-Tuong Nguyen
-
Publication number: 20040068380Abstract: The invention provides isolated nucleic acids that encode human GRBP2, and fragments thereof, vectors for propagating and expressing human GRBP2 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the human GRBP2, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human GRBP2 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human GRBP2 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the human GRBP2 nucleic acids, proteins, and antibodies of the present invention.Type: ApplicationFiled: September 15, 2003Publication date: April 8, 2004Inventor: Mark E. Shannon
-
Publication number: 20040063134Abstract: The invention provides isolated nucleic acids that encode three novel isoforms of human pregnancy associated plasma protein E, hPAPP-E, and fragments thereof, vectors for propagating and expressing PAPP-E nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel PAPP-E isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human PAPP-E isoform nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human PAPP-E gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the PAPP-E nucleic acids, proteins, and antibodies of the present invention.Type: ApplicationFiled: September 30, 2003Publication date: April 1, 2004Inventors: Yizhong Gu, Mark E. Shannon
-
Patent number: 6686188Abstract: Presented are a novel myosin-like protein particularly expressed in human heart and muscle, isolated nucleic acids encoding the myosin-like protein, compounds and compositions derivable directly or indirectly therefrom, and diagnostic and therapeutic methods for using the same.Type: GrantFiled: May 25, 2001Date of Patent: February 3, 2004Assignee: Amersham PLCInventors: Yizhong Gu, Yonggang Ji, Sharron Gaynor Penn, David Kagen Hanzel, David Russell Rank, Wensheng Chen, Mark E. Shannon
-
Patent number: 6656700Abstract: The invention provides isolated nucleic acids that encode three novel isoforms of human pregnancy associated plasma protein E, hPAPP-E, and fragments thereof, vectors for propagating and expressing PAPP-E nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel PAPP-E isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human PAPP-E isoform nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human PAPP-E gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the PAPP-E nucleic acids, proteins, and antibodies of the present invention.Type: GrantFiled: April 6, 2001Date of Patent: December 2, 2003Assignee: Amersham PLCInventors: Yizhong Gu, Mark E. Shannon
-
Publication number: 20020123474Abstract: The invention provides isolated nucleic acids that encode human GRBP2, and fragments thereof, vectors for propagating and expressing human GRBP2 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the human GRBP2, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human GRBP2 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human GRBP2 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the human GRBP2 nucleic acids, proteins, and antibodies of the present invention.Type: ApplicationFiled: June 29, 2001Publication date: September 5, 2002Inventors: Mark E. Shannon, Yonggang Ji
-
Publication number: 20020102252Abstract: The invention provides isolated nucleic acids that encode three novel isoforms of human pregnancy associated plasma protein E, hPAPP-E, and fragments thereof, vectors for propagating and expressing PAPP-E nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel PAPP-E isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human PAPP-E isoform nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human PAPP-E gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the PAPP-E nucleic acids, proteins, and antibodies of the present invention.Type: ApplicationFiled: April 6, 2001Publication date: August 1, 2002Inventors: Yizhong Gu, Mark E. Shannon
-
Publication number: 20020048800Abstract: Presented are a novel myosin-like protein particularly expressed in human heart and muscle, isolated nucleic acids encoding the myosin-like protein, compounds and compositions derivable directly or indirectly therefrom, and diagnostic and therapeutic methods for using the same.Type: ApplicationFiled: May 25, 2001Publication date: April 25, 2002Inventors: Yizhong Gu, Yonggang Ji, Sharron G. Penn, David K. Hanzel, David R. Rank, Wensheng Chen, Mark E. Shannon